The FDA recall list covers syringes prefilled with various medications produced at the manufacturer’s compounding center in West Columbia, S.C. Nephron told The State the recall is a precautionary measure.
“Out of an abundance of caution, Nephron is proactively cooperating with the Food and Drug Administration on a voluntary recall of a limited number of product lots,” Lou Kennedy, CEO of Nephron, said in a statement. “We do not take this lightly. While there has been no impact to patient safety and there is no evidence of contamination, Nephron has decided in the interest of patients to proceed with this recall process. The company is prepared to provide the resources and information necessary to healthcare providers and patients to make certain they have anything they need and any questions answered. They remain our top priority.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
